Core Viewpoint - BioMarin Pharmaceutical Inc. is raising $850 million through the issuance of senior unsecured notes to finance its acquisition of Amicus Therapeutics, Inc. and related expenses [1][2][3] Financing Details - The company priced its offering of $850 million of 5.500% senior unsecured notes due in 2034 at an issue price of 100.000% [1] - BioMarin completed the syndication of a new $2 billion senior secured term loan "B" facility, in addition to an existing $800 million senior secured term loan "A" facility and a $600 million senior secured revolving credit facility [2] - The net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will be used to fund the acquisition and related fees [3] Redemption and Guarantees - Gross proceeds from the notes will be held in an escrow account until the acquisition is completed; if not completed by December 19, 2026, the notes will be redeemed at 100% of the initial issue price plus accrued interest [4] - The notes will be jointly and severally guaranteed by certain subsidiaries of BioMarin, including Amicus and its subsidiaries after the acquisition [5] Covenants and Restrictions - The indenture governing the notes will include customary covenants that restrict BioMarin and its subsidiaries from incurring additional debt, paying dividends, and other specified actions [6] Company Overview - BioMarin is a global biotechnology company focused on rare diseases, with a strong track record of innovation and a robust pipeline of therapies [9][10]